Bafna Pharmaceuticals logo

Bafna Pharmaceuticals

BAFNAPH NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹728 Cr
Volatility
Moderate
P/E Ratio
91.63
EBITDA
₹1.50 Cr
Return on Equity
-3.68%
Debt to Equity
0.39
Book Value
₹40.64
52W High
₹318.5
52W Low
₹94.77

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Weaknesses

5
  • Stock is trading at 7.42 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Tax rate seems low
  • Company has a low return on equity of 9.88% over last 3 years.
  • Earnings include an other income of Rs.6.07 Cr.

Growth Rate

Revenue Growth
-2.95% lower than 3Y
Net Income Growth
-90.21% lower than 3Y
Cash Flow Change
—
ROE
-96.42% lower than 3Y
ROCE
-90.07% lower than 3Y
EBITDA Margin (Avg.)
-112% higher than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
41.95
40.68
28.44
41.4
33.29
40.32
33.19
39.06
34.62
35.47
38.29
42.24
26.58
Expenses
35.66
36.67
30.51
38.51
32.08
36.53
30.13
35.95
29.55
31.19
35.24
38.69
25.69
Operating Profit
6.29
4.01
-2.07
2.89
1.21
3.79
3.06
3.11
5.07
4.28
3.05
3.55
0.89
OPM %
14.99%
9.86%
-7.28%
6.98%
3.63%
9.4%
9.22%
7.96%
14.64%
12.07%
7.97%
8.4%
3.35%
Other Income
1.87
0.16
0.98
0.52
0.16
1.02
0.18
-0.76
0.6
1.18
1.22
1.76
1.91
Interest
0.6
0.44
0.58
0.68
0.65
0.62
0.64
0.82
0.91
0.86
0.86
1.03
0.94
Depreciation
1.21
1.24
1.27
1.27
1.44
1.58
1.66
0.22
1.37
1.47
1.57
1.66
1.78
PBT
6.35
2.49
-2.94
1.46
-0.72
2.61
0.94
1.31
3.39
3.13
1.84
2.62
0.08
Tax %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
-4.96%
0%
Net Profit
6.35
2.48
-2.94
1.46
-0.72
2.62
0.95
1.31
3.39
3.12
1.84
2.75
0.08
EPS in Rs
2.68
1.05
-1.24
0.62
-0.3
1.11
0.4
0.55
1.43
1.32
0.78
1.16
0.03
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
100
85
65
46
44
42
71
85
115
152
146
151
143
Expenses
116
82
70
81
57
41
61
73
100
141
135
135
131
Operating Profit
-16
3
-5
-35
-13
1
10
12
16
11
11
16
12
OPM %
-16%
3.3%
-8%
-77%
-30%
2.9%
14%
14%
14%
7%
8%
11%
8%
Other Income
40
1
1
31
0
-23
1
0
3
4
1
5
6
Interest
12
12
11
7
2
0
1
1
2
2
3
4
4
Depreciation
5
4
4
4
3
3
4
5
5
5
5
6
6
PBT
6
-13
-19
-14
-18
-25
6
5
12
7
4
11
8
Tax %
0%
-3%
-4%
15%
8%
0%
0%
0%
2%
0%
0%
-1%
—
Net Profit
6
-12
-18
-16
-20
-25
6
5
11
7
4
11
8
EPS in Rs
3.28
-6.53
-9.9
-6.95
-8.34
-107
2.46
2.21
4.79
3.11
1.75
4.69
3.29
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
19
19
19
24
24
2
24
24
24
24
24
24
Reserves
53
41
26
17
-3
49
33
38
50
57
61
72
Borrowings
64
80
82
47
46
3
15
11
23
24
28
37
Other Liabilities
50
45
40
40
54
17
14
17
33
42
40
42
Total Liabilities
185
185
167
128
121
71
86
90
130
148
153
176
Fixed Assets
49
47
43
40
37
35
36
39
40
40
59
82
CWIP
0
0
0
0
0
0
1
0
2
12
7
3
Investments
18
18
18
1
1
0
0
0
0
0
0
0
Other Assets
118
120
106
86
82
36
50
51
88
95
87
91
Total Assets
185
185
167
128
121
71
86
90
130
148
153
176
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
9
-3
14
-7
-1
-34
-14
10
5
9
22
15
Investing
56
-1
-8
38
4
33
-5
-7
-7
-15
-21
-22
Financing
-66
4
-5
-31
-2
7
12
-5
10
-1
1
6
Net Cash Flow
0
0
0
0
0
6
-7
-2
8
-6
2
-1
Free Cash Flow
2
-5
20
40
-1
-36
-20
2
-2
-6
0
-10
CFO/OP
-74
-106
-263
20
8
-2,786
-132
83
32
87
194
94
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
303
291
302
195
208
52
49
63
130
109
101
106
Inventory Days
66
92
118
102
122
208
154
185
129
125
127
129
Days Payable
149
169
164
265
517
229
107
113
165
149
140
139
Cash Conversion Cycle
220
214
255
31
-188
31
96
135
94
84
88
96
Working Capital Days
56
125
-36
-108
-210
89
121
123
104
92
74
74
ROCE %
-13%
0%
-6%
-35%
-21%
-3%
10%
11%
16%
9%
8%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Bafna Pharmaceuticals insights

66 extracted metrics + investor summaries across FY09–FY26.

Log in — free

Shareholding Pattern

Others3.69%Promot.75.00%FIIs9.34%Public11.97%As ofJun 2026

Documents

Frequently Asked Questions about Bafna Pharmaceuticals

What does Bafna Pharmaceuticals Ltd do?
Incorporated in 1981, Bafna Pharmaceuticals Ltd manufactures finished pharmaceutical formulations[1]
Where is Bafna Pharmaceuticals Ltd (BAFNAPH) listed?
Bafna Pharmaceuticals Ltd trades as BAFNAPH on the NSE and under code 532989 on the BSE.
Which sector does Bafna Pharmaceuticals Ltd belong to?
Bafna Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd has a market capitalisation of ₹727.67 Cr, which places it in the Small Cap band.
What is the PE ratio of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd trades at a PE ratio of 91.63, against a book value of ₹40.64 per share.
What is the 52-week high and low of Bafna Pharmaceuticals Ltd?
Over the last 52 weeks Bafna Pharmaceuticals Ltd has traded between ₹94.77 and ₹318.5.
What is the Return on Equity (ROE) of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd reported a return on equity of -3.68%. Its debt-to-equity ratio is 0.39.

Company Information

Incorporated in 1981, Bafna Pharmaceuticals Ltd manufactures finished pharmaceutical formulations[1]

Website bafnapharma.com
CEO Mr. Bansilal Mahaveer Chand Bafna
Employees 406
Listed 2020-02-27
Face Value ₹ 10
Issued Size 2,36,56,335

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BAFNAPH.md for Bafna Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List